Explore

Rapid Read Rapid Read
Retatrutide Shows Promise in Weight Management, Awaits FDA Approval

Retatrutide Shows Promise in Weight Management, Awaits FDA Approval

Retatrutide, a drug not yet approved by the FDA, has shown significant promise in weight management during phase 2 trials, with participants losing an average of 24.2% of body weight over 48 weeks. This triple agonist drug activates three hormonal receptors, enhancing metabolic benefits. Despite its potential, access to retatrutide is currently limited to clinical trials and compounding pharmacies, with regulatory approval anticipated in the coming years.
Trendline Trendline
Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model

Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model

Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model
Trendline Trendline
GLP-1 Weight-Loss Medication Users Face Unexpected Relationship Challenges

GLP-1 Weight-Loss Medication Users Face Unexpected Relationship Challenges

GLP-1 Weight-Loss Medication Users Face Unexpected Relationship Challenges
Trendline Trendline
Peptides Gain Popularity in Wellness Industry Amid Regulatory Concerns

Peptides Gain Popularity in Wellness Industry Amid Regulatory Concerns

Peptides Gain Popularity in Wellness Industry Amid Regulatory Concerns
Rapid Read Rapid Read
Researchers Identify Brain Receptor Mechanism for Weight Loss Drugs

Researchers Identify Brain Receptor Mechanism for Weight Loss Drugs

Researchers at the Institute of Metabolic Science, University of Cambridge, have discovered how both stimulating and blocking a brain receptor, GIPR, can aid in weight loss. The study, conducted on mice, revealed that stimulating GIPR in the brainstem suppresses appetite, while blocking it in the hypothalamus achieves a similar effect. This research could lead to the development of more effective obesity treatments. The study highlights the role of dual agonists for the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) in managing type 2 diabetes and obesity. The findings suggest that GIPR agonists and antagonists act on different brain regions, enhancing weight loss when combined with GLP-1-based drugs.
Rapid Read Rapid Read
FDA Advisory Committee Recommends Lifting Regulations on Experimental Peptides Amidst Safety Concerns

FDA Advisory Committee Recommends Lifting Regulations on Experimental Peptides Amidst Safety Concerns

A U.S. drug advisory committee has recommended that the FDA lift regulations on several experimental peptides, allowing select pharmacies to manufacture and doctors to prescribe them. This decision comes despite the lack of large-scale human trials to support the safety and efficacy of these compounds. Peptides, which are short chains of amino acids, are being marketed for a variety of health benefits, including anti-aging and injury healing. The unregulated market for these peptides is estimated to be worth between $100 million and $3 billion. The committee's recommendation aims to mitigate risks associated with purchasing these products from unregulated sources, but it also raises concerns about the message it sends regarding their safety.
Trendline Trendline
Muscle Method Program Promotes Weight Loss Through Structured Workouts

Muscle Method Program Promotes Weight Loss Through Structured Workouts

Muscle Method Program Promotes Weight Loss Through Structured Workouts
Rapid Read Rapid Read
Retatrutide Emerges as a Potential Successor to Semaglutide in Obesity Treatment

Retatrutide Emerges as a Potential Successor to Semaglutide in Obesity Treatment

Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, is gaining attention as a potential successor to semaglutide for obesity treatment. Unlike semaglutide, which targets only the GLP-1 receptor, retatrutide's broader mechanism may offer enhanced metabolic effects and greater weight loss. Phase 2 clinical trials have shown promising results, with participants losing up to 24% of body weight over 48 weeks. However, retatrutide is still investigational and lacks FDA approval. Patients transitioning from semaglutide to retatrutide are advised to start at a low dose and follow a structured titration schedule to minimize side effects.
Trendline Trendline
GLP-1 Weight Loss Drugs Impacting Personal Relationships

GLP-1 Weight Loss Drugs Impacting Personal Relationships

GLP-1 Weight Loss Drugs Impacting Personal Relationships
Trendline Trendline
Calocurb Supplement Shows Promising Weight Loss Results Without Muscle Loss

Calocurb Supplement Shows Promising Weight Loss Results Without Muscle Loss

Calocurb Supplement Shows Promising Weight Loss Results Without Muscle Loss
Trendline Trendline
Food Network's Katie Lee Discusses Positive Experience with GLP-1 Medication

Food Network's Katie Lee Discusses Positive Experience with GLP-1 Medication

Food Network's Katie Lee Discusses Positive Experience with GLP-1 Medication
Rapid Read Rapid Read
Study Shows Potential Benefits of Combining HRT and GLP-1 for Menopausal Women

Study Shows Potential Benefits of Combining HRT and GLP-1 for Menopausal Women

A recent study published by the Mayo Clinic in The Lancet has shown that postmenopausal women taking tirzepatide alongside hormone replacement therapy (HRT) experienced significant weight loss compared to those on tirzepatide alone. The study, which followed 120 women, found that those on the combination treatment lost 19.2% of their body weight, compared to 14% for those on tirzepatide alone. This observational study suggests that the combination of HRT and GLP-1 receptor agonists may enhance treatment effectiveness, although the authors caution that the results are not from a randomized trial. The study highlights the potential for these treatments to work better together, with estrogen amplifying GLP-1 signaling and improving outcomes.